David W. Gibbs Files Initial Statement of Beneficial Ownership for Amgen Inc.

Executive Summary

On October 27, 2026, Amgen Inc. ($AMGN) filed an initial statement of beneficial ownership (Form 3) with the SEC on behalf of newly reporting Director David W. Gibbs. The event date is reported as October 26, 2026.

Key Findings

• Reporting Person: David W. Gibbs, designated as a Director of Amgen Inc.
• Reported Holdings: The filing explicitly indicates <noSecuritiesOwned>1</noSecuritiesOwned>, reporting zero shares of common stock or derivative securities held directly or indirectly at the time of appointment.
• Transaction Activity: None. This filing is an initial baseline disclosure under Section 16(a) of the Securities Exchange Act of 1934.
• Supporting Documentation: Includes an Exhibit 24 Power of Attorney appointing Andrea A. Robinson and Dennis Yai as attorneys-in-fact for future Section 16 filings.

Market & Governance Implications

Form 3 filings of this nature are administrative requirements when an individual becomes subject to Section 16 reporting obligations (such as election to the Board of Directors). Because no shares were acquired or disposed of on the open market, this filing carries Low trading significance and represents neutral market sentiment.